HBM 9033
Alternative Names: HBM-9033; MesoC2; PF-08052666; SGN-MesoC2Latest Information Update: 16 Jun 2025
At a glance
- Originator Nona Biosciences
- Developer Nona Biosciences; Seagen
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical trial in Solid tumours were presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 02 Aug 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT06466187)
- 04 Jul 2024 Seagen plans a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) (IV) (NCT06466187)